Skip to content

Draft, not yet released. In stewardship review. Not indexed until the first approved release.

Risks and capability

Four genomics risk objects open the portfolio. Order carries no rank. Each is read across driver, exposure, vulnerability, capacity, cascade and consequence.

8 min read0 figures1 table27 notesNR-XTECH-GENOMICS-GLOBAL-2026-BASELINE

目录
  1. ·Edition home
  2. ·Executive summary
  3. 1Genomics is data infrastructure and a therapeutic frontier
  4. 2Key findings
  5. 3Systems and sectors at baseline
  6. 4Risks and capability
    1. 4.1 Risk objects
    2. 4.2 Capability ladder
  7. 5Individualised editing outpaces delivery systems
  8. 6Readings from the other desks
  9. 7The 2027 agenda
  10. 8Systems in depth
  11. A方法论
  12. BData appendix
  13. CReferences and record
  14. ·Complete edition, for print

4.1Risk objects

Each risk is read across the chain from hazard to consequence, with its status and evidence-quality level.

  1. InferredEQL 3RSK-XT05-HLT-001

    Safety events in in vivo editing

    驱动因素
    high-dose delivery and new targets910
    风险暴露
    patients in early trials
    脆弱性
    small trials; short follow-up
    能力
    clinical holds, monitoring and review927
    级联
    HLT → FIN, GOV
    地平线
    1 to 5 years
  2. InferredEQL 3RSK-XT05-DAT-002

    Genetic data ownership and privacy

    驱动因素
    sale of a large genetic database in bankruptcy3238
    风险暴露
    millions of customers
    脆弱性
    consent and state-by-state rules; weak federal limits
    能力
    state privacy laws and non-discrimination law44
    级联
    DAT → FIN, HLT
    地平线
    1 to 5 years
  3. InferredEQL 3RSK-XT05-TRD-003

    Sequencer and consumable supply politics

    驱动因素
    trade controls and procurement law3031
    风险暴露
    laboratories relying on one instrument family
    脆弱性
    few suppliers; reagent supply not assessed
    能力
    new entrants and alternative platforms15
    级联
    TRD → INF → DAT
    地平线
    1 to 5 years
  4. InferredEQL 3RSK-XT05-GOV-004

    Uneven oversight of editing

    驱动因素
    differing national rules and a fast-moving bespoke pathway52936
    风险暴露
    cross-border treatment and research
    脆弱性
    heritable-editing rules differ; some rely on soft law284142
    能力
    WHO framework and summit statements2728
    级联
    GOV → HLT, FIN
    地平线
    1 to 10 years

4.2Capability ladder

Existence is not readiness. Each of the fifteen capability functions is placed on the ladder by the strongest public evidence for genomics at the global level.

Table 4.1Capabilities on the ladder of evidence: listed, exists, demonstrated, tested
职能Rung级别Strongest public evidence at baseline
Prevention and mitigationEXISTSnewborn and population screening programmes running34
Monitoring and observationLISTEDno common tracker of treatment counts or long-term safety
早期预警LISTEDsafety signals reach the public through company disclosures9
Preparedness and planningEXISTSWHO framework and approval pathways1527
Redundancy and reservesLISTEDinstrument and reagent reserves are not documented
响应EXISTSclinical holds and monitoring rules were applied in 20259
Continuity of critical servicesLISTEDcold-chain continuity for cell therapies not documented
恢复LISTEDnot applicable at baseline
AdaptationEXISTSnew pathways for individualised therapies are being drafted537
社会保护LISTEDaccess in low-income settings is limited8
金融与保险LISTEDprice negotiations ongoing; payer data not bound7
Institutional coordinationEXISTSsummits and WHO governance work2728
Technical infrastructureEXISTSreference genomes and biobanks available111617
劳动力LISTEDgenetic counsellor numbers known; wider workforce not bound33
Research capacityADEQUATEstrong peer-reviewed base2111224
A capability listed in policy is not a tested one; each rung is the strongest public evidence at baseline.

Notes

Numbers are the edition’s reference numbers, so a note reads the same in every chapter. The full list, with every source and its licence, is in Annex C. Annex C, references

  1. 9BioSpace (ed.), Life-threatening liver toxicity triggers FDA freeze on two Intellia gene therapy studies (trade press, 30 October 2025; relays company disclosures; secondary report, weak evidence). BioSpace, Boston. Observation year 2025. Accessed 2026-11-03.back
  2. 10Lek, A. et al., Death after High-Dose rAAV9 Gene Therapy in a Patient with Duchenne Muscular Dystrophy, New England Journal of Medicine 2023 (abstract read through the Europe PMC record). Massachusetts Medical Society, Waltham. Observation year 2023. Accessed 2026-11-03.back
  3. 27World Health Organization (ed.), Human genome editing: a framework for governance (technical document, 12 July 2021; companion recommendations published separately and not read). WHO, Geneva. Observation year 2021. Accessed 2026-11-03.back
  4. 32MedTech Dive (ed.), Anne Wojcicki bid to buy 23andMe in bankruptcy (trade press, 17 June 2025; USD 305 million bid against a USD 256 million bid; state objections; secondary report, weak evidence). Industry Dive, Washington. Observation year 2025. Accessed 2026-11-03.back
  5. 38NPR (ed.), Judge OKs sale of 23andMe, and its trove of DNA data, to a nonprofit led by its founder, by J. Ruwitch, 30 June 2025 (story read through the syndicated copy on KPBS; TTAM Research Institute won with a USD 305 million bid after a USD 256 million Regeneron bid; several states opposed the sale). NPR, Washington. Observation year 2025. Accessed 2026-11-05.back
  6. 44United States Congress (ed.), Genetic Information Nondiscrimination Act of 2008, Public Law 110-233, 122 Stat. 881, 21 May 2008 (enrolled text read; prohibits discrimination on the basis of genetic information in health insurance and employment). US Government Publishing Office, Washington. Observation year 2008. Accessed 2026-11-05.back
  7. 30Latham and Watkins (ed.), BIOSECURE Act becomes law, limiting grants with biotechnology companies of concern (law-firm summary; enacted 18 December 2025 in the FY2026 NDAA; OMB list due by 18 December 2026; secondary source of a statute). Latham and Watkins, Los Angeles. Observation year 2025. Accessed 2026-11-03.back
  8. 31MedTech Dive (ed.), China to lift Illumina export ban (trade press, November 2025; listing in February 2025, import ban in March 2025, lift on 10 November 2025, instrument sales in China down 54% in the third quarter; secondary report, weak evidence). Industry Dive, Washington. Observation year 2025. Accessed 2026-11-03.back
  9. 15Ultima Genomics (ed.), germline genetics product page (vendor claim of a USD 60 genome at list price over 4 wafers on the UG200 series; the browser title reads USD 80; vendor evidence, weak). Ultima Genomics, Newark. Observation year 2026. Accessed 2026-11-03.back
  10. 5Clinical Trials Arena (ed.), FDA unveils new pathway to usher bespoke therapies to market (trade press, 13 November 2025; describes the plausible mechanism pathway announced in a journal article by the FDA Commissioner and the CBER Director; secondary report, weak evidence). Clinical Trials Arena, London. Observation year 2025. Accessed 2026-11-03.back
  11. 29UK Parliament (ed.), Genetic Technology (Precision Breeding) Act 2023, 2023 c. 6 (contents page read; section texts not read). UK Parliament, London. Observation year 2023. Accessed 2026-11-03.back
  12. 36European Parliament and Council of the European Union (eds.), Regulation (EU) 2026/1388 of 17 June 2026 on plants obtained by certain new genomic techniques and their products, and amending Regulation (EU) 2017/625, Official Journal L series, 26 June 2026 (text read; enters into force on the twentieth day after publication; applies from 17 July 2028, with Articles 29 to 31 from 16 July 2026). Publications Office of the European Union, Luxembourg. Observation year 2026. Accessed 2026-11-05.back
  13. 28Royal Society (ed.), Statement from the Organising Committee of the Third International Summit on Human Genome Editing (8 March 2023; convened by the Royal Society, the Academy of Medical Sciences, the US National Academies and The World Academy of Sciences). Royal Society, London. Observation year 2023. Accessed 2026-11-03.back
  14. 41Council of Europe (ed.), Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology and Medicine (Oviedo Convention), Oviedo, 4 April 1997 (text read in the official Spanish publication, Boletin Oficial del Estado BOE-A-1999-20638, 20 October 1999; in force since 1 December 1999; article 13 allows an intervention to modify the human genome only if it does not aim to modify the genome of descendants). Council of Europe, Strasbourg. Observation year 1997. Accessed 2026-11-05.back
  15. 42Lander, E.S. et al., Adopt a moratorium on heritable genome editing, Nature 567 (7747), 165 to 168, 2019 (record read via Crossref). Springer Nature, London. Observation year 2019. Accessed 2026-11-05.back
  16. 34Genomics England (ed.), Generation Study: newborn genome sequencing (initiative page; 100,000 babies; more than 200 conditions; recruitment progress not stated). Genomics England, London. Observation year 2026. Accessed 2026-11-03.back
  17. 1US Food and Drug Administration (ed.), FDA approves first gene therapies to treat patients with sickle cell disease (press announcement, 8 December 2023; Casgevy uses CRISPR/Cas9, Lyfgenia a lentiviral vector; patients 12 years and older). FDA, Silver Spring. Observation year 2023. Accessed 2026-11-03.back
  18. 37US Food and Drug Administration (ed.), Considerations for the Use of the Plausible Mechanism Framework To Develop Individualized Therapies That Target Specific Genetic Conditions With Known Biological Cause; Draft Guidance for Industry; Availability, Federal Register 91 (37), notice 2026-03713, docket FDA-2026-D-1256, 25 February 2026 (notice read; the draft covers genome editing and RNA-based therapies; comments due 27 April 2026; the guidance text itself was not read). FDA, Silver Spring. Observation year 2026. Accessed 2026-11-05.back
  19. 8Montano-Campos, J.F. et al., Cost-effectiveness of gene therapy for sickle cell disease in Uganda: tailoring high-income evidence to Uganda context, Gene Therapy 2026 (abstract read through the Europe PMC record). Springer Nature, London. Observation year 2026. Accessed 2026-11-03.back
  20. 7Chetlapalli, K. et al., Haploidentical transplant, gene therapy, and standard care in sickle cell disease: a cost-effectiveness analysis, Blood 2026 (abstract read through the Europe PMC record; gene therapy access limited by cost and manufacturing capacity). American Society of Hematology, Washington. Observation year 2026. Accessed 2026-11-03.back
  21. 11Nurk, S. et al., The complete sequence of a human genome, Science 2022 (abstract read through the Europe PMC record; 3.055 billion base pairs; nearly 200 million base pairs of new sequence). American Association for the Advancement of Science, Washington. Observation year 2022. Accessed 2026-11-03.back
  22. 16UK Biobank Whole-Genome Sequencing Consortium, Whole-genome sequencing of 490,640 UK Biobank participants, Nature 2025 (abstract read through the Europe PMC record). Springer Nature, London. Observation year 2025. Accessed 2026-11-03.back
  23. 17All of Us Research Program Genomics Investigators, Genomic data in the All of Us Research Program, Nature 2024 (abstract read through the Europe PMC record; 245,388 genomes; 77% from communities under-represented in research). Springer Nature, London. Observation year 2024. Accessed 2026-11-03.back
  24. 33US Bureau of Labor Statistics (ed.), Occupational Outlook Handbook: Genetic Counselors (about 4,200 jobs in 2025; median pay USD 100,040 in May 2025; 10% growth projected 2025 to 2035). BLS, Washington. Observation year 2025. Accessed 2026-11-03.back
  25. 2Frangoul, H. et al., Exagamglogene Autotemcel for Severe Sickle Cell Disease, New England Journal of Medicine 2024 (abstract read through the Europe PMC record; 44 treated, 30 evaluable, 29 free of crises for 12 months or more). Massachusetts Medical Society, Waltham. Observation year 2024. Accessed 2026-11-03.back
  26. 12Liao, W.-W. et al. (Human Pangenome Reference Consortium), A draft human pangenome reference, Nature 2023 (abstract read through the Europe PMC record; 47 phased diploid assemblies; 119 million base pairs added). Springer Nature, London. Observation year 2023. Accessed 2026-11-03.back
  27. 24Jinek, M. et al., A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity, Science 2012 (abstract read through the Europe PMC record). American Association for the Advancement of Science, Washington. Observation year 2012. Accessed 2026-11-03.back

Downloads

Draft, not yet releasedReview copies of a draft in stewardship review. The released edition carries its DOI and replaces them.

  • 打印

    • PDF, A4

      The designed print edition, A4: cover, imprint and licence, how to cite, contents with page numbers, every chapter, figure, table and annex.

      PDF113 pages1.0 MBTagged, with bookmarks

      SHA-256 7276b0b0c2919661f94a296cdb60a579d1cb5466d3fab3011f46a9d5e81e42d6

    • PDF, US Letter

      The designed print edition, US Letter: cover, imprint and licence, how to cite, contents with page numbers, every chapter, figure, table and annex.

      PDF123 pages1.0 MBTagged, with bookmarks

      SHA-256 da38a3579fdd5a3ac5c84f44a22853584be7e987208657578ede146f7b88fd58

  • Web edition

  • 数据包

    • Indicators, CSV

      16 indicators with unit, year, status and source

      NR-XTECH-GENOMICS-GLOBAL-2026-BASELINE-indicators.csv1 KB

      SHA-256 f1c3fc5ae9f6823c263bb4a464c29a9516551ab806ef2a07fc3e737d1cd85a8d

    • Indicators, JSON

      The same indicators with the edition’s identity and licence

      NR-XTECH-GENOMICS-GLOBAL-2026-BASELINE-indicators.json2 KB

      SHA-256 c54a918f9a805a488a8931ec6c1a235eb273361704df0909aae23d83048aa489

    • Findings, CSV

      12 findings with status, evidence-quality level and references

      NR-XTECH-GENOMICS-GLOBAL-2026-BASELINE-findings.csv3 KB

      SHA-256 0cb51833261dd188ca2af8a452aa38bbf651743f01a98776ff39430d07bcb97f

  • Citation files

    • Citation, BibTeX

      For LaTeX and reference managers

      NR-XTECH-GENOMICS-GLOBAL-2026-BASELINE.bib1 KB

      SHA-256 a09328c6428b83ba58eba3284cc50b50417b9fccd1c4d685a53746ed430fac83

    • Citation, RIS

      For Zotero, EndNote and Mendeley

      NR-XTECH-GENOMICS-GLOBAL-2026-BASELINE.ris1 KB

      SHA-256 95ff0d92b09d48fa348d982302647ab3ab0709cf5aaccccde30e735cade45a16

    • Citation, CITATION.cff

      Citation File Format 1.2.0, for GitHub, Zenodo and software catalogues

      NR-XTECH-GENOMICS-GLOBAL-2026-BASELINE.cff1 KB

      SHA-256 16aeb56c4b5eb0bfe8917c7848aec9209776f6cf7708280877069c0cfe0ef1f2

Check a file with its SHA-256: shasum -a 256 <file> (macOS, Linux) or Get-FileHash <file> (Windows). Text, tables and figures by Nexus: CC BY 4.0; each source keeps its own licence.

Cite this chapter

Valadbaygi, S. (Ed.). (2026). Chapter 4: Risks and capability. In Exponential Technology Report 2026: Genomics and Gene Editing (Baseline Edition 2026, Report No. NR-XTECH-GENOMICS-GLOBAL-2026-BASELINE) [Draft under review]. The Global Centre for Risk and Innovation (GCRI).

Every citation form of the whole report, BibTeX and RIS included, is on the edition home. Cite this report

报告贡献

Send evidence or a correction on Genomics and Gene Editing.

Reports is the Consortium’s quarterly publication, written by six desks. This page sits with the Global Centre for Risk and Innovation (GCRI) Systems Evidence desk. What you know about this subject can become evidence, a case or a correction in the next edition, credited to you and published under CC BY 4.0 where it is your own work. Sent to the wrong desk, it is forwarded, not refused.

GCRI Systems 证据编辑部指数级技术

CC BY 4.0 Free to read. Text and figures: CC BY 4.0. Data: CC0 1.0. Authors keep copyright. Published by GCRI Canada.

Your role here

What you can do from this page.

  • ReaderFound an error? Every correction is public.Corrections log
  • ContributorSend evidence, data or a correction to this desk.Contribute
  • ReviewerReview for this desk; verified reviews are credited.Become a reviewer
  • Editor, steward or boardQueues, decisions and production are in the workspace.My workspace